藥物釋放型支架市場規模、佔有率和成長分析：按產品類型、藥物類型、應用、材質、最終用戶、世代和地區分類－2026-2033年產業預測

2024 年全球藥物釋放型支架 (DES) 市值為 89 億美元，預計到 2025 年將成長至 95.3 億美元，到 2033 年將成長至 165 億美元，在預測期（2026-2033 年）內複合年成長率為 7.1%。

全球藥物釋放型支架（DES）市場在心臟治療中發揮著至關重要的作用，其核心在於研發能夠釋放抗增殖藥物以預防冠狀動脈介入治療後血管再阻塞再狹窄的裝置。由於第二代DES相比裸金屬支架具有更優異的性能，該市場經歷了顯著成長並廣泛應用。從早期的Sirolimus塗層支架到生物可吸收和無聚合物設計，DES的進步使其確立了標準治療地位。監管支援和保險報銷策略進一步推動了這一成長，並促進了創新技術的應用。此外，門診導管檢查室數量的增加也推動了快速部署裝置的需求。人工智慧影像分析技術的引入提高了手術精度和患者預後，從而推動了尖端支架平台的應用，並有望實現市場大幅擴張。

全球藥物釋放型支架市場的成長要素

隨著微創心臟治療的日益普及，心臟科醫師擴大選擇藥物釋放型支架，以最大限度地降低再血管再阻塞風險並縮短恢復時間。這種轉變不僅增加了手術數量，也增強了臨床醫生的信心，並提高了患者對這些先進療法的興趣。此外，醫療機構也意識到減少再次介入帶來的長期經濟效益，從而為投資這些先進醫療設備提供了合理的理由。這一趨勢正在促進醫療設備製造商和醫療機構之間的合作，加速公共和私人醫療部門對創新解決方案的採用，並最終推動全球藥物釋放型支架市場的成長。

全球藥物釋放型支架市場的限制因素

由於嚴格的法規核准要求，全球藥物釋放型支架市場面臨嚴峻挑戰。監管機構制定了嚴格的標準，要求提供全面的臨床證據來證明其安全性和長期療效，這導致產品上市時間延長，研發成本增加。如此嚴苛的核准流程阻礙了中小型製造商進入市場，限制了創新設計的供應，並抑制了市場成長。因此，醫療機構可能無法及時獲得先進技術，影響其應用率，並可能導致繼續依賴過時的設備。這種情況也可能導致臨床醫生延遲從傳統植入過渡到新型藥物洗脫支架。

藥物釋放型支架市場的全球趨勢

全球藥物釋放型支架市場正呈現顯著的個人化趨勢。這主要歸功於製造商擴大採用客製化的藥物釋放型平台，以滿足患者的個別需求和特定病變特徵。這種創新方法融合了先進的成像技術、生物標記分析和可客製化的塗層技術，在改善治療效果的同時，最大限度地減少了副作用。臨床醫生現在可以選擇針對各種冠狀動脈疾病最佳化的藥物和劑量組合，從而推動生產流程朝著更靈活的方向發展。這種對個人化解決方案日益成長的關注也促進了醫療設備製造商、製藥公司和精準醫療服務提供者之間的策略合作，從而在全球市場中創造了競爭優勢。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 宏觀經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球藥物釋放型支架市場規模：依產品類型分類

• 以聚合物為基礎的藥物釋放型支架
• 無聚合物藥物釋放型支架
• 可生物分解聚合物藥物釋放型支架

全球藥物釋放型支架市場規模：依藥物類型分類

• Sirolimus洗脫支架
• Everolimus洗脫支架
• 佐他莫司洗脫支架
• 紫杉醇洗脫支架
• 其他

全球藥物釋放型支架市場規模：依應用領域分類

• 冠狀動脈疾病
• 周邊動脈疾病
• 其他

全球藥物釋放型支架市場規模：依材質分類

• 鈷鉻合金支架
• 鉑鉻合金支架
• 不銹鋼支架
• 其他

全球藥物釋放型支架市場規模：依最終用戶分類

• 醫院
• 心臟導管檢查室
• 門診手術中心

全球藥物釋放型支架市場規模：依世代分類

• 第一代藥物釋放型支架
• 第二代藥物釋放型支架
• 下一代藥物釋放型支架

全球藥物釋放型支架市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• BIOTRONIK SE & Co. KG
• Terumo Corporation
• B. Braun Melsungen AG
• MicroPort Scientific Corporation
• Lepu Medical Technology（Beijing）Co., Ltd.
• Meril Life Sciences Pvt. Ltd.
• Sahajanand Medical Technologies Limited
• Cook Medical LLC
• Alvimedica Medical Technologies
• Translumina Therapeutics LLP
• SINOMED
• Balton Sp. z oo
• OrbusNeich Medical Group Holdings Limited
• Elixir Medical Corporation
• Cordis Corporation
• JW Medical Systems Ltd.
• Shandong Weigao Group Medical Polymer Company Limited

結論與建議

Global Drug Eluting Stent Market size was valued at USD 8.9 Billion in 2024 and is poised to grow from USD 9.53 Billion in 2025 to USD 16.5 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).

The global drug-eluting stent (DES) market is pivotal in cardiac care, focusing on devices that deliver antiproliferative medications to prevent restenosis after coronary interventions. This market has experienced significant growth due to the superior performance of second-generation DES over bare-metal alternatives, leading to widespread adoption. Advancements from early sirolimus-coated stents to bio-resorbable and polymer-free designs have normalized DES as the standard of care. Regulatory support and reimbursement strategies further catalyze this growth, promoting the adoption of innovative technologies. Additionally, the rise of outpatient catheterization labs has increased demand for rapid deployment devices. The introduction of AI-driven image analysis is enhancing procedural accuracy and patient outcomes, thereby encouraging the adoption of cutting-edge stent platforms and positioning the market for significant expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Eluting Stent market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Eluting Stent Market Segments Analysis

Global drug eluting stent market is segmented by product type, drug type, application, material type, end user, generation and region. Based on product type, the market is segmented into Polymer-Based Drug-Eluting Stents, Polymer-Free Drug-Eluting Stents and Biodegradable Polymer Drug-Eluting Stents. Based on drug type, the market is segmented into Sirolimus-Eluting Stents, Everolimus-Eluting Stents, Zotarolimus-Eluting Stents, Paclitaxel-Eluting Stents and Others. Based on application, the market is segmented into Coronary Artery Disease, Peripheral Artery Disease and Others. Based on material type, the market is segmented into Cobalt-Chromium Stents, Platinum-Chromium Stents, Stainless Steel Stents and Others. Based on end user, the market is segmented into Hospitals, Cardiac Catheterization Laboratories and Ambulatory Surgical Centers. Based on generation, the market is segmented into First-Generation Drug-Eluting Stents, Second-Generation Drug-Eluting Stents and Next-Generation Drug-Eluting Stents. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Drug Eluting Stent Market

The increasing inclination towards minimally invasive cardiac procedures is driving cardiologists to choose drug-eluting stents, which minimize the risk of restenosis and promote quicker recovery times. This shift not only enhances procedural volumes but also boosts clinician confidence and patient interest in these advanced options. Moreover, healthcare organizations recognize the long-term financial advantages of fewer repeat interventions, justifying investment in such sophisticated devices. This trend fosters collaboration between device manufacturers and clinical institutions, facilitating the rapid adoption of innovative solutions in both public and private healthcare sectors, ultimately contributing to the growth of the global drug-eluting stent market.

Restraints in the Global Drug Eluting Stent Market

The Global Drug Eluting Stent market faces significant challenges due to stringent regulatory requirements for approval. Regulatory agencies impose rigorous standards that necessitate comprehensive clinical evidence to demonstrate safety and long-term effectiveness, resulting in extended timeframes for market entry and increased development expenditures. Such demanding approval processes deter smaller manufacturers from participating, which in turn restricts the availability of innovative designs and hampers market growth. As a result, healthcare providers may experience delays in accessing advanced technologies, impacting adoption rates and potentially leading to a continued dependence on outdated devices. This situation may cause clinicians to delay transitioning from traditional implant options.

Market Trends of the Global Drug Eluting Stent Market

The Global Drug Eluting Stent market is witnessing a significant trend towards personalization, as manufacturers increasingly adopt tailored drug-eluting platforms that cater to individual patient needs and specific lesion characteristics. This innovative approach enhances therapeutic outcomes while minimizing adverse effects by incorporating advanced imaging techniques, biomarker profiling, and customizable coating technologies. Clinicians are enabled to select optimal drug-dosage combinations tailored to various coronary conditions, fostering a shift towards more flexible production processes. This growing emphasis on personalized solutions is also promoting strategic collaborations among device manufacturers, pharmaceutical companies, and precision-medicine providers, thereby creating a competitive edge in the global market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Drug Eluting Stent Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Polymer-Based Drug-Eluting Stents
• Polymer-Free Drug-Eluting Stents
• Biodegradable Polymer Drug-Eluting Stents

Global Drug Eluting Stent Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Sirolimus-Eluting Stents
• Everolimus-Eluting Stents
• Zotarolimus-Eluting Stents
• Paclitaxel-Eluting Stents
• Others

Global Drug Eluting Stent Market Size by Application & CAGR (2026-2033)

• Market Overview
• Coronary Artery Disease
• Peripheral Artery Disease
• Others

Global Drug Eluting Stent Market Size by Material Type & CAGR (2026-2033)

• Market Overview
• Cobalt-Chromium Stents
• Platinum-Chromium Stents
• Stainless Steel Stents
• Others

Global Drug Eluting Stent Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cardiac Catheterization Laboratories
• Ambulatory Surgical Centers

Global Drug Eluting Stent Market Size by Generation & CAGR (2026-2033)

• Market Overview
• First-Generation Drug-Eluting Stents
• Second-Generation Drug-Eluting Stents
• Next-Generation Drug-Eluting Stents

Global Drug Eluting Stent Market Size & CAGR (2026-2033)

• North America (Product Type, Drug Type, Application, Material Type, End User, Generation)
  • US
  • Canada
• Europe (Product Type, Drug Type, Application, Material Type, End User, Generation)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Drug Type, Application, Material Type, End User, Generation)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Drug Type, Application, Material Type, End User, Generation)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Drug Type, Application, Material Type, End User, Generation)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOTRONIK SE & Co. KG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lepu Medical Technology (Beijing) Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meril Life Sciences Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sahajanand Medical Technologies Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvimedica Medical Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Translumina Therapeutics LLP
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SINOMED
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Balton Sp. z o.o.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OrbusNeich Medical Group Holdings Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elixir Medical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cordis Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JW Medical Systems Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shandong Weigao Group Medical Polymer Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations